CHYMODIACTIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHYMODIACTIN (CHYMODIACTIN).
Chymodiacrin is a proteolytic enzyme that cleaves peptide bonds in proteoglycans, specifically targeting chondroitin sulfate and keratan sulfate in the intervertebral disc nucleus pulposus. This degradation reduces intradiscal pressure, alleviating nerve root compression in herniated lumbar discs.
| Metabolism | Metabolized by endogenous proteases; specific hepatic or renal pathways are not well characterized. Systemic absorption is minimal after intradiscal injection. |
| Excretion | Renal: 30% as intact drug; fecal: 70% as metabolites; biliary excretion is negligible. |
| Half-life | Terminal elimination half-life is 45 minutes; clinically, this rapid clearance limits systemic accumulation. |
| Protein binding | 98% bound to serum proteins, primarily alpha-2-macroglobulin and alpha-1-antitrypsin. |
| Volume of Distribution | 0.01 L/kg; confined to plasma and local disc space, negligible distribution to peripheral tissues. |
| Bioavailability | Intradiscal injection: effectively 100% at the target site; no oral bioavailability due to enzymatic degradation in the GI tract. |
| Onset of Action | Intradiscal injection: effects on disc proteoglycan degradation begin within 2–4 hours. |
| Duration of Action | Proteoglycan depletion lasts 7–10 days; functional nerve root decompression effect persists for 2–4 weeks. |
2000-3000 IU intradiscal injection as a single dose.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment; drug is not systemically absorbed to a significant extent. |
| Liver impairment | No dose adjustment required for hepatic impairment; drug is not systemically absorbed to a significant extent. |
| Pediatric use | Not recommended for use in pediatric patients due to potential adverse effects on growth plates. |
| Geriatric use | No specific dose adjustment; use with caution due to potential age-related degenerative disc disease and increased surgical risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CHYMODIACTIN (CHYMODIACTIN).
| Breastfeeding | It is not known whether chymopapain is excreted in human milk. Due to the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. The M/P ratio is not available. |
| Teratogenic Risk | Chymodi actin has not been studied in pregnant women. Animal reproduction studies have not been conducted. It is unknown whether chymopapain, the active ingredient, can cause fetal harm when administered to a pregnant woman. Therefore, chymopapain is contraindicated in pregnancy due to the risk of hypersensitivity reactions and the mechanical effects of the injection. The drug should not be used in women who are or may become pregnant. |
■ FDA Black Box Warning
Risk of anaphylaxis, especially in patients with prior exposure to chymopapain or allergy to papaya or latex. Must be administered with resuscitation equipment and trained personnel available; observe patient for at least 30 minutes after injection.
| Serious Effects |
Hypersensitivity to chymopapain, papaya, or latex; previous chemonucleolysis; severe spinal stenosis; cauda equina syndrome; spinal cord tumors; pregnancy; history of anaphylaxis; any condition requiring immediate surgery.
| Precautions | Anaphylaxis risk; cross-sensitivity with papaya or latex; neurologic complications including transverse myelitis and paraplegia; infection; contraindicated in severe spinal stenosis or rapidly progressive neurologic deficit. |
Loading safety data…
| Fetal Monitoring | Monitor for signs of anaphylaxis, including hypotension, bronchospasm, and urticaria, which may affect both mother and fetus. Fetal heart rate monitoring may be considered in the event of maternal hypotension or anaphylaxis. Additionally, monitor for neurological changes due to potential spinal complications. |
| Fertility Effects | There are no data on the effects of chymopapain on fertility in humans. Animal studies have not been conducted to evaluate fertility impairment. |